Research programme: cell therapies - Astellas Institute for Regenerative Medicine

Drug Profile

Research programme: cell therapies - Astellas Institute for Regenerative Medicine

Latest Information Update: 21 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ocata Therapeutics
  • Developer Astellas Institute for Regenerative Medicine
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders
  • Research Corneal disorders

Most Recent Events

  • 29 Dec 2015 Early research in Corneal disorders in USA (unspecified route)
  • 24 Aug 2015 Ocata Therapeutics receives SBIR grant from the National Institute of Allergy and Infectious Diseases for hemangio-derived mesenchymal cell development in systemic lupus erythematosus and lupus nephritis
  • 16 Mar 2015 Research programme: hemangio derived mesenchymal cells - Ocata Therapeutics is available for licensing as of 16 Mar 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top